+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Boehringer Ingelheim International GmbH - Strategic SWOT Analysis Review

Boehringer Ingelheim International GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Boehringer Ingelheim International GmbH (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for swine, ruminant, poultry, horses and pets among others. Boehringer is headquartered in Ingelheim, Rheinland-Pfalz, Germany.

Boehringer Ingelheim International GmbH Key Recent Developments

  • Jan 11, 2024: Boehringer expands production site in Greece for new medicine
  • Jan 03, 2024: Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
  • Dec 18, 2023: Boehringer Ingelheim Announces Appointments Board of Managing Directors
  • Dec 06, 2023: Ten63 Therapeutics Announces Multi-Target Drug Discovery Collaboration with Boehringer Ingelheim

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with a detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Boehringer Ingelheim International GmbH - Key Facts
  • Boehringer Ingelheim International GmbH - Key Employees
  • Boehringer Ingelheim International GmbH - Key Employee Biographies
  • Boehringer Ingelheim International GmbH - Major Products and Services
  • Boehringer Ingelheim International GmbH - History
  • Boehringer Ingelheim International GmbH - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Boehringer Ingelheim International GmbH - Business Description
  • R&D Overview
  • Boehringer Ingelheim International GmbH - Corporate Strategy
  • Boehringer Ingelheim International GmbH - SWOT Analysis
  • SWOT Analysis - Overview
  • Boehringer Ingelheim International GmbH - Strengths
  • Boehringer Ingelheim International GmbH - Weaknesses
  • Boehringer Ingelheim International GmbH - Opportunities
  • Boehringer Ingelheim International GmbH - Threats
  • Boehringer Ingelheim International GmbH - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Boehringer Ingelheim International GmbH, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • Jan 11, 2024: Boehringer expands production site in Greece for new medicine
  • Jan 03, 2024: Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
  • Dec 18, 2023: Boehringer Ingelheim Announces Appointments Board of Managing Directors
  • Dec 06, 2023: Ten63 Therapeutics Announces Multi-Target Drug Discovery Collaboration with Boehringer Ingelheim
  • Nov 07, 2023: Boehringer Ingelheim and Ambio Sign Cooperation Development Agreement for Innovative Drugs for Inflammatory Diseases
  • Oct 30, 2023: Life Forward - Boehringer Ingelheim Unveils Its Evolved Company Brand
  • Oct 06, 2023: Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund’s 2023 Corporate Membership Program at ‘Champion’ Level
  • Oct 02, 2023: Boehringer Ingelheim Partners with Precision Health Research, Singapore to Bring Future Medical Breakthroughs to Patients
  • Oct 02, 2023: Zeiss and Boehringer Ingelheim Are Working Together on the Early Detection of Eye Diseases and the Prevention of Vision Loss
  • Sep 14, 2023: Boehringer Ingelheim Receives SBTi Validation for CO2 Reduction Targets
Section 5 - Appendix
  • Methodology
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Boehringer Ingelheim International GmbH, Key Facts
  • Boehringer Ingelheim International GmbH, Key Employees
  • Boehringer Ingelheim International GmbH, Key Employee Biographies
  • Boehringer Ingelheim International GmbH, Major Products and Services
  • Boehringer Ingelheim International GmbH, History
  • Boehringer Ingelheim International GmbH, Other Locations
  • Boehringer Ingelheim International GmbH, Subsidiaries
  • Boehringer Ingelheim International GmbH, Key Competitors
  • Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Boehringer Ingelheim International GmbH, Recent Deals Summary
List of Figures
  • Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Eli Lilly and Co
  • AbbVie Inc
  • Novartis AG
  • GSK plc
  • Bristol-Myers Squibb Co
  • Pfizer Inc
  • Fresenius SE & Co KGaA
  • F. Hoffmann-La Roche Ltd
  • AnaptysBio Inc
  • Eli Lilly and Co
  • Novartis AG
  • Bristol-Myers Squibb Co
  • Pfizer Inc
  • Phibro Animal Health Corp
  • F. Hoffmann-La Roche Ltd